lilly novo nordisk - Search News

News

Novo Nordisk, Lilly

Reuters on MSN · 3d

Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial. The data is the first head-to-head trial comparing the wildly popular medicines,

Indianapolis Business Journal · 1d

Novo Nordisk inks $2.2B deal to develop weight-loss pill to rival Lilly’s orforglipron

Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last month.

Investing.com · 2d

Eli Lilly Vs. Novo Nordisk: Which Pharma Stock Is Likely to Do Better in 2025?

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and 5% lower for operating profit than expected, reflects lower GLP-1 penetration in the US market.

FDA Accepts Novo Nordisk’s Application for Oral Wegovy: 5 Things to Know

Federal regulators have accepted Novo Nordisk’s application to produce a pill version of its injectable weight-loss ...

Fierce Biotech1d

Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Novo Doubles Down on Oral Obesity Meds With Septerna Deal Worth up to $2.4B

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Novo Nordisk strikes deal with Septerna to develop obesity pills

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results